CA
NZ
UK
AU
IND
US
…
BSF Enterprise Plc, together with its subsidiaries, develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong. The company acquires businesses in the biotechnology, marketing, and e-commerce sectors. It also engages in biotechnology start-up; lab-grown cornea and meat research; and development of skin technology. The company was incorporated in 2018 and is based in London, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | -1.22M | -1.80M | -1.58M | -0.93M | -0.06M |
| Net income | -1.11M | -1.67M | -1.50M | -0.93M | -0.06M |
| Selling general administrative | 0.73M | 0.96M | 0.92M | 0.66M | 0.09M |
| Selling and marketing expenses | - | 0.03M | 0.02M | 0.01M | - |
| Gross profit | -0.13M | -0.03M | -0.09M | -0.16M | - |
| Reconciled depreciation | 0.11M | 0.11M | 0.11M | 0.02M | - |
| Ebit | -1.21M | -1.79M | -1.57M | -0.93M | -0.06M |
| Ebitda | -1.10M | -1.68M | -1.46M | -0.91M | -0.06M |
| Depreciation and amortization | 0.11M | 0.11M | 0.11M | 0.02M | 0.00M |
| Operating income | -1.64M | -1.79M | -1.57M | -0.93M | -0.06M |
| Other operating expenses | 1.69M | 1.85M | 1.58M | 0.93M | 0.06M |
| Interest expense | 0.00M | 0.01M | 0.01M | 0.00M | 0.00M |
| Tax provision | -0.10M | -0.13M | -0.08M | 0.00M | 0.00M |
| Interest income | 0.00M | 0.00M | 0.00M | - | - |
| Net interest income | -0.00M | -0.01M | -0.01M | -0.00M | -0.00M |
| Income tax expense | -0.10M | -0.13M | -0.08M | 0.00M | 0.00M |
| Total revenue | 0.05M | 0.06M | 0.01M | 0.00M | 0.00M |
| Total operating expenses | 1.51M | 1.76M | 1.48M | 0.77M | 0.06M |
| Cost of revenue | 0.18M | 0.08M | 0.10M | 0.16M | - |
| Total other income expense net | 0.42M | -0.01M | -0.01M | -0.00M | -0.00M |
| Net income from continuing ops | -1.11M | -1.67M | -1.50M | -0.93M | -0.06M |
| Net income applicable to common shares | - | - | - | -0.93M | -0.06M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 3.01M | 3.50M | 5.26M | 4.03M | 0.40M |
| Intangible assets | - | - | 2.49M | - | - |
| Other current assets | 0.00M | 0.08M | 0.15M | 0.17M | 0.04M |
| Total liab | 0.29M | 0.31M | 0.40M | 0.45M | 0.04M |
| Total stockholder equity | 2.72M | 3.19M | 4.86M | 3.58M | 0.36M |
| Other current liab | 0.17M | 0.01M | -0.00M | 0.17M | 0.02M |
| Common stock | 1.28M | 1.03M | 1.03M | 0.86M | 0.20M |
| Capital stock | 1.28M | 1.03M | 1.03M | 0.86M | 0.20M |
| Retained earnings | -5.29M | -4.17M | -2.50M | -1.00M | -0.25M |
| Other liab | - | - | - | 0.01M | - |
| Good will | 2.49M | 2.49M | 2.49M | - | - |
| Cash | 0.15M | 0.64M | 2.32M | 1.06M | 0.36M |
| Total current liabilities | 0.28M | 0.29M | 0.30M | 0.30M | 0.04M |
| Net debt | -0.15M | -0.56M | -2.16M | -0.83M | -0.36M |
| Short term debt | - | 0.16M | 0.16M | 0.07M | - |
| Short long term debt total | - | 0.08M | 0.16M | 0.23M | - |
| Other stockholder equity | 6.66M | 6.29M | 6.29M | 3.72M | 0.41M |
| Property plant equipment | - | - | - | 0.30M | - |
| Total current assets | 0.47M | 0.86M | 2.52M | 1.25M | 0.40M |
| Net tangible assets | - | - | - | 1.10M | 0.36M |
| Net receivables | 0.23M | 0.08M | 0.01M | 0.15M | 0.03M |
| Inventory | 0.09M | 0.06M | 0.05M | 0.02M | - |
| Accounts payable | 0.11M | 0.06M | 0.09M | 0.06M | 0.01M |
| Accumulated other comprehensive income | 0.06M | 0.04M | 0.03M | - | - |
| Non current assets total | 2.54M | 2.64M | 2.74M | 2.78M | 0.00M |
| Capital lease obligations | 0.00M | 0.08M | 0.16M | 0.23M | - |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Investments | - | -0.01M | -0.06M | 0.00M | - |
| Change to liabilities | - | - | - | 0.13M | 0.00M |
| Total cashflows from investing activities | -0.01M | -0.01M | -0.06M | 0.00M | 0.00M |
| Net borrowings | - | - | - | -0.01M | -0.01M |
| Total cash from financing activities | 0.53M | -0.08M | 2.70M | 1.37M | 1.37M |
| Change to operating activities | - | - | - | -0.10M | -0.10M |
| Net income | -1.11M | -1.67M | -1.50M | -0.93M | -0.06M |
| Change in cash | -0.49M | -1.68M | 1.26M | 0.70M | -0.09M |
| Begin period cash flow | 0.64M | 2.32M | 1.06M | 0.36M | 0.45M |
| End period cash flow | 0.15M | 0.64M | 2.32M | 1.06M | 0.36M |
| Total cash from operating activities | -1.01M | -1.59M | -1.38M | -0.67M | -0.09M |
| Issuance of capital stock | 0.64M | 0.00M | 2.95M | 1.75M | - |
| Depreciation | 0.11M | 0.11M | 0.11M | 0.02M | 0.02M |
| Change to inventory | -0.02M | -0.02M | -0.02M | - | - |
| Change to account receivables | -0.13M | 0.00M | -0.03M | 0.03M | -0.03M |
| Sale purchase of stock | - | - | - | -0.37M | - |
| Other cashflows from financing activities | -0.08M | -0.08M | -0.17M | -0.01M | -0.37M |
| Change to netincome | - | - | - | 0.18M | 0.18M |
| Capital expenditures | 0.01M | 0.01M | 0.06M | 0.01M | 0.01M |
| Change in working capital | -0.02M | -0.03M | -0.03M | 0.07M | -0.03M |
| Stock based compensation | 0.02M | 0.00M | -0.01M | - | - |
| Other non cash items | 0.02M | -0.00M | 0.04M | 0.18M | - |
| Free cash flow | -1.02M | -1.60M | -1.44M | -0.68M | -0.09M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BSFA BSF Enterprise Plc |
-0.12 11.63% |
0.95 | - | - | 41.01 | 0.08 | 1.48 | -13.12 |
| GNS Genus PLC |
18.00 0.78% |
2340.00 | 36.08 | 26.18 | 2.53 | 3.46 | 2.92 | 15.38 |
| ONT Oxford Nanopore Technologies Ltd |
10.60 4.93% |
225.60 | - | - | 4.71 | 2.50 | 4.23 | -8.89 |
| OXB Oxford BioMedica PLC |
5.00 0.95% |
532.00 | - | 208.33 | 4.05 | 7.60 | 4.42 | 308.96 |
| AVCT Avacta Group PLC |
-1.00 1.60% |
61.50 | - | - | 2849.46 | 1929.84 | 2525.51 | -12.04 |
BSF Enterprise Plc, together with its subsidiaries, develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong. The company acquires businesses in the biotechnology, marketing, and e-commerce sectors. It also engages in biotechnology start-up; lab-grown cornea and meat research; and development of skin technology. The company was incorporated in 2018 and is based in London, the United Kingdom.
| Name | Title | Year Born |
|---|---|---|
| Mr. Geoffrey Robert Baker B.Com., LL.B., MBA | Company Sec. & Non-Exec. Director | 1956 |
| Dr. Che John Connon | CEO, MD & Executive Director | 1972 |
| Mr. Graham John William Duncan | Chief Financial Officer | 1963 |
| Mr. Ricardo Gouveia | C.S.O | NA |
| Mr. Marcelo Bravo | Chief Business Officer | NA |
| Mr. Geoffrey Robert Baker B.Com., L.L.B., M.B.A. | Executive Chairman | 1956 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...